The multi-target aspect of an MmpL3 inhibitor: The BM212 series of compounds bind EthR2, a transcriptional regulator of ethionamide activation-Reference-Cited by-同舟云学术

The multi-target aspect of an MmpL3 inhibitor: The BM212 series of compounds bind EthR2, a transcriptional regulator of ethionamide activation

Published:2021-12 Issue: Volume:7 Page:100068
ISSN:2468-2330
Container-title:The Cell Surface
language:en
Short-container-title:The Cell Surface

Author:

Moorey Alice R.,Cabanillas Alejandro,Batt Sarah M.,Ghidelli-Disse Sonja,Urones Beatriz,Sanz Olalla,Lelievre Joel,Bantscheff Marcus,Cox Liam R.,Besra Gurdyal S.

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Applied Microbiology and Biotechnology,Microbiology

Reference78 articles.

1. Identification of KasA as the cellular target of an anti-tubercular scaffold;Abrahams;Nat. Commun.,2016

2. An ethA-ethR-deficient Mycobacterium bovis BCG mutant displays increased adherence to mammalian cells and greater persistence in vivo, which correlate with altered mycolic acid composition;Ang;Infect. Immun.,2014

3. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis;Banerjee;Science,1994

4. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes;Bantscheff;Nat. Biotechnol.,2011

5. The thick waxy coat of mycobacteria, a protective layer against antibiotics and the host’s immune system;Batt;Biochem. J.,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polypharmacology-Driven Discovery and Design of Highly Selective, Dual and Multitargeting Inhibitors of Mycobacterium tuberculosis - A Review;Current Drug Targets;2024-07

2. Synthesis, biological evaluation and docking studies of silicon incorporated diarylpyrroles as MmpL3 inhibitors: An effective strategy towards development of potent anti-tubercular agents;European Journal of Medicinal Chemistry;2023-11

3. Recent advances in mycobacterial membrane protein large 3 inhibitor drug design for mycobacterial infections;Expert Opinion on Drug Discovery;2023-06-04

4. Targeting mycobacterial membranes and membrane proteins: Progress and limitations;Bioorganic & Medicinal Chemistry;2023-03

5. A Hydrazine–Hydrazone Adamantine Compound Shows Antimycobacterial Activity and Is a Probable Inhibitor of MmpL3;Molecules;2022-10-21